 |
 Previous Article
The Journal of Neuroscience, July 15, 1998, 18(14):5545-5554
Corticolimbic Dopamine Neurotransmission Is Temporally
Dissociated from the Cognitive and Locomotor Effects of
Phencyclidine
Barbara
Adams and
Bita
Moghaddam
Department of Psychiatry, Yale University School of Medicine,
Veterans Administration Medical Center, West Haven, Connecticut
06516
The behavioral syndrome produced by phencyclidine (PCP) and its
analog ketamine represents a pharmacological model for some aspects of
schizophrenia. Despite the multifaceted properties of these drugs, the
main mechanism for their psychotomimetic and cognitive-impairing
effects has been thought heretofore to involve the corticolimbic
dopamine system. The present study examined the temporal relationship
between alterations in corticolimbic dopamine and glutamate
neurotransmission and two dopamine-dependent behavioral effects of PCP
in the rodent that have relevance to the clinical phenomenology,
namely, impairment of working memory, which is used to model the
frontal lobe deficits associated with schizophrenia, and
hyperlocomotion, which is used as a predictor of the propensity of a
drug to elicit or exacerbate psychosis. PCP increased dopamine and
glutamate efflux in the prefrontal cortex and nucleus accumbens, as
measured by microdialysis. The increase in dopamine in both regions
remained elevated well above baseline 2.5 hr after the injection, at
which time the experiment was terminated. However, locomotor activity
returned to baseline in <2 hr after injection. Furthermore, impaired
performance in a discrete trial delayed alternation task, a rodent
working memory task, was only evident up to 60 min after PCP injection;
animals tested 80 min after injection, when cortical dopamine release was elevated at 300% of baseline, did not exhibit impaired
performance. These findings indicate that activation of dopamine
neurotransmission is not sufficient to sustain PCP-induced locomotion
and impairment of working memory. Thus, effects of PCP, including a
glutamatergic hyperstimulation, may be necessary to account for the
psychotomimetic and cognitive-impairing effects of this drug.
Key words:
prefrontal cortex; nucleus accumbens; microdialysis; PCP; schizophrenia; working memory; glutamate; NMDA; ketamine; drug
abuse
Copyright © 1998 Society for Neuroscience 0270-6474/98/18145545-10$05.00/0
This article has been cited by other articles:
|
|
|
|
 
J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al.
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
Pharmacol. Rev.,
September 1, 2008;
60(3):
358 - 403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kargieman, N. Santana, G. Mengod, P. Celada, and F. Artigas
Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine
PNAS,
September 11, 2007;
104(37):
14843 - 14848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Stone, P. D. Morrison, and L. S. Pilowsky
Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review
J Psychopharmacol,
June 1, 2007;
21(4):
440 - 452.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. A. Rabiner
Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?
J Psychopharmacol,
May 1, 2007;
21(3):
253 - 258.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. H. Large
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
J Psychopharmacol,
May 1, 2007;
21(3):
283 - 301.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Z. Gu, Q. Jiang, and Z. Yan
RGS4 Modulates Serotonin Signaling in Prefrontal Cortex and Links to Serotonin Dysfunction in a Rat Model of Schizophrenia
Mol. Pharmacol.,
April 1, 2007;
71(4):
1030 - 1039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bespalov, A.-L. Jongen-Relo, M. van Gaalen, S. Harich, H. Schoemaker, and G. Gross
Habituation Deficits Induced by Metabotropic Glutamate Receptors 2/3 Receptor Blockade in Mice: Reversal by Antipsychotic Drugs
J. Pharmacol. Exp. Ther.,
February 1, 2007;
320(2):
944 - 950.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Brandish, C.-S. Chiu, J. Schneeweis, N. J. Brandon, C. L. Leech, O. Kornienko, E. M. Scolnick, B. Strulovici, and W. Zheng
A Cell-Based Ultra-High-Throughput Screening Assay for Identifying Inhibitors of D-Amino Acid Oxidase
J Biomol Screen,
August 1, 2006;
11(5):
481 - 487.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. O. Cunningham, J. Hunt, S. Middleton, F. E. N. LeBeau, M. G. Gillies, C. H. Davies, P. R. Maycox, M. A. Whittington, and C. Racca
Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness.
J. Neurosci.,
March 8, 2006;
26(10):
2767 - 2776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Homayoun and B. Moghaddam
Bursting of Prefrontal Cortex Neurons in Awake Rats is Regulated by Metabotropic Glutamate 5 (mGlu5) Receptors: Rate-dependent Influence and Interaction with NMDA Receptors
Cereb Cortex,
January 1, 2006;
16(1):
93 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Yang and L. Chen
Targeting Prefrontal Cortical Dopamine D1 and N-Methyl-D-Aspartate Receptor Interactions in Schizophrenia Treatment
Neuroscientist,
October 1, 2005;
11(5):
452 - 470.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Homayoun, M. E. Jackson, and B. Moghaddam
Activation of Metabotropic Glutamate 2/3 Receptors Reverses the Effects of NMDA Receptor Hypofunction on Prefrontal Cortex Unit Activity in Awake Rats
J Neurophysiol,
April 1, 2005;
93(4):
1989 - 2001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Hunt, K. Kessal, and R. Garcia
Ketamine Induces Dopamine-Dependent Depression of Evoked Hippocampal Activity in the Nucleus Accumbens in Freely Moving Rats
J. Neurosci.,
January 12, 2005;
25(2):
524 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Abdul-Monim, G. P. Reynolds, and J. C. Neill
The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat
J Psychopharmacol,
January 1, 2003;
17(1):
57 - 66.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Ferraro, M. C. Tomasini, G. L. Gessa, B. W. Bebe, S. Tanganelli, and T. Antonelli
The Cannabinoid Receptor Agonist WIN 55,212-2 Regulates Glutamate Transmission in Rat Cerebral Cortex: an In Vivo and In Vitro Study
Cereb Cortex,
August 1, 2001;
11(8):
728 - 733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Phillips, C. Wang, and K. M. Johnson
Pharmacological Characterization of Locomotor Sensitization Induced by Chronic Phencyclidine Administration
J. Pharmacol. Exp. Ther.,
March 1, 2001;
296(3):
905 - 913.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. E. Jackson and B. Moghaddam
Amygdala Regulation of Nucleus Accumbens Dopamine Output is Governed by the Prefrontal Cortex
J. Neurosci.,
January 15, 2001;
21(2):
676 - 681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Miyamoto, K. Yamada, Y. Noda, H. Mori, M. Mishina, and T. Nabeshima
Hyperfunction of Dopaminergic and Serotonergic Neuronal Systems in Mice Lacking the NMDA Receptor {epsilon}1 Subunit
J. Neurosci.,
January 15, 2001;
21(2):
750 - 757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. K. Lambe, L. S. Krimer, and P. S. Goldman-Rakic
Differential Postnatal Development of Catecholamine and Serotonin Inputs to Identified Neurons in Prefrontal Cortex of Rhesus Monkey
J. Neurosci.,
December 1, 2000;
20(23):
8780 - 8787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Otani, N. Auclair, J.-M. Desce, M.-P. Roisin, and F. Crepel
Dopamine Receptors and Groups I and II mGluRs Cooperate for Long-Term Depression Induction in Rat Prefrontal Cortex through Converging Postsynaptic Activation of MAP Kinases
J. Neurosci.,
November 15, 1999;
19(22):
9788 - 9802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cartmell, J. A. Monn, and D. D. Schoepp
The Metabotropic Glutamate 2/3 Receptor Agonists LY354740 and LY379268 Selectively Attenuate Phencyclidine versus d-Amphetamine Motor Behaviors in Rats
J. Pharmacol. Exp. Ther.,
October 1, 1999;
291(1):
161 - 170.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. B. Farber, J. W. Newcomer, and J. W. Olney
Glycine Agonists: What Can They Teach Us About Schizophrenia?
Arch Gen Psychiatry,
January 1, 1999;
56(1):
13 - 17.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Moghaddam and B. W. Adams
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Science,
August 28, 1998;
281(5381):
1349 - 1352.
[Abstract]
[Full Text]
|
|
|
|
